XORTX Therapeutics (XRTX) Receivables (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Receivables came in at $64633.0 in Q1 2026, up 274.64% YoY from $17252.0 in Q1 2025, and down 19.38% on a QoQ basis from $80172.0 in Q4 2025.
XORTX Therapeutics (XRTX) Receivables (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Receivables data on file, last reported at $64633.0 in Q1 2026.
- Quarterly Receivables rose 274.64% year-over-year to $64633.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64633.0 (up 274.64% YoY) and the FY2025 annual result came in at $80172.0, up 354.57% from the prior year.
- Receivables fell to $64633.0 in Q1 2026, from $80172.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $195583.2 in Q2 2022 to a low of $10860.0 in Q2 2025.
- A 5-year average of $55395.9 and a median of $36421.0 in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables slumped 84.45% — and 2025, when it surged 354.57%.
- Tracing XRTX's Receivables over 5 years: stood at $81575.1 in 2022, then retreated by 25.58% to $60711.0 in 2023, then plunged by 70.95% to $17637.0 in 2024, then jumped by 354.57% to $80172.0 in 2025, then retreated by 19.38% to $64633.0 in 2026.
- The last three Receivables figures came in at $64633.0 (Q1 2026), $80172.0 (Q4 2025), and $22092.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 64,633.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64,633.00 |
| Dec 31, 2025 | 80,172.00 |
| Sep 30, 2025 | 22,092.00 |
| Jun 30, 2025 | 10,860.00 |
| Mar 31, 2025 | 17,252.00 |
| Dec 31, 2024 | 17,637.00 |
| Sep 30, 2024 | 13,111.00 |
| Jun 30, 2024 | 22,807.00 |
| Mar 31, 2024 | 30,883.00 |
| Dec 31, 2023 | 60,711.00 |
| Sep 30, 2023 | 68,241.00 |
| Jun 30, 2023 | 30,414.00 |
| Mar 31, 2023 | 36,421.00 |
| Dec 31, 2022 | 81,575.12 |
| Sep 30, 2022 | 66,358.82 |
| Jun 30, 2022 | 195,583.19 |
| Mar 31, 2022 | 122,979.74 |
| Dec 31, 2021 | 40,887.75 |
| Dec 31, 2020 | 11,008.00 |